These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33910316)

  • 1. [Progress in the treatment of multiple myeloma with daratumumab].
    Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):260-264. PubMed ID: 33910316
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
    Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
    [No Abstract]   [Full Text] [Related]  

  • 3. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
    Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
    Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
    Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Attal M; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Chiu C; Wang J; Van Rampelbergh R; Uhlar CM; Kobos R; Qi M; Usmani SZ;
    N Engl J Med; 2019 May; 380(22):2104-2115. PubMed ID: 31141632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P;
    N Engl J Med; 2016 Oct; 375(14):1319-1331. PubMed ID: 27705267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
    Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
    Krejcik J; Frerichs KA; Nijhof IS; van Kessel B; van Velzen JF; Bloem AC; Broekmans MEC; Zweegman S; van Meerloo J; Musters RJP; Poddighe PJ; Groen RWJ; Chiu C; Plesner T; Lokhorst HM; Sasser AK; Mutis T; van de Donk NWCJ
    Clin Cancer Res; 2017 Dec; 23(24):7498-7511. PubMed ID: 29025767
    [No Abstract]   [Full Text] [Related]  

  • 9. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.
    Mizuno S; Kitayama C; Mashiko S; Sanada S
    CEN Case Rep; 2022 May; 11(2):265-268. PubMed ID: 34817845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
    Laubach JP; Paba Prada CE; Richardson PG; Longo DL
    Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
    Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
    Takamatsu H; Iida S; Shibayama H; Shibayama K; Yamazaki H; Suzuki K
    Int J Hematol; 2020 May; 111(5):692-701. PubMed ID: 32002821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
    Touzeau C; Antier C; Moreau P
    Future Oncol; 2021 Mar; 17(9):993-998. PubMed ID: 33289427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab plus lenalidomide and dexamethasone
    Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
    Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab for the treatment of multiple myeloma.
    Touzeau C; Moreau P
    Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; Nijhof IS; van de Donk NWCJ; Katodritou E; Schjesvold F; Sureda Balari A; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; Lonergan S; Ahmadi T; Liu Y; Wang J; Vieyra D; van Brummelen EMJ; Vanquickelberghe V; Sitthi-Amorn A; de Boer CJ; Carson R; Rodriguez-Otero P; Bladé J; Moreau P;
    N Engl J Med; 2024 Jan; 390(4):301-313. PubMed ID: 38084760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
    Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
    Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
    Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
    Wong XY; Chng WJ; Aziz MIA; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):207-215. PubMed ID: 34904498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.